ACH
AEGR

ArrowMark Colorado Holdings’s Aegerion Pharmaceuticals AEGR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,860
Closed -$244K – 319
2013
Q2 		$244K Buy
+3,860
New +$205K 0.07% 113

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ArrowMark Colorado Holdings's AEGR Position: Q3 2013 in Review

ArrowMark Colorado Holdings sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2013, closing a stake of 3,860 shares — an estimated $244K sold.

ArrowMark Colorado Holdings first reported a position in AEGR in Q2 2013 and held it in 1 quarter. The position peaked at $244K in Q2 2013. 154 funds tracked by Wall St. Rank hold AEGR as of Q3 2013.

  • ArrowMark Colorado Holdings reported no remaining Aegerion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 3,860 Aegerion Pharmaceuticals shares in Q3 2013, an estimated $244K.
  • ArrowMark Colorado Holdings first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • ArrowMark Colorado Holdings's Aegerion Pharmaceuticals position peaked at $244K in Q2 2013.
  • 154 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2013.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2013, filed 14 Nov 2013.